Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis

The Lancet Diabetes and Endocrinology

Volumn 5, Issue 7, 2017, Pages 524-533

  Saleheen, Danish ^a,b   Haycock, Philip C ^c,d   Zhao, Wei ^a,e   Rasheed, Asif ^b   Taleb, Adam ^f   Imran, Atif ^b   Abbas, Shahid ^g   Majeed, Faisal ^b   Akhtar, Saba ^b   Qamar, Nadeem ^h   Zaman, Khan Shah ^h   Yaqoob, Zia ^h   Saghir, Tahir ^h   Rizvi, Syed Nadeem Hasan ^h   Memon, Anis ^h   Mallick, Nadeem Hayyat ⁱ   Ishaq, Mohammad ^j   Rasheed, Syed Zahed ^j   Memon, Fazal ur Rehman ^k   Mahmood, Khalid ^l   Ahmed, Naveeduddin ^l   Frossard, Philippe ^b   Tsimikas, Sotirios ^f   Witztum, Joseph L ^f   Marcovina, Santica ^m   Sandhu, Manjinder ^c,n   Rader, Daniel J ^e,o   Danesh, John ^c,n   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Centre for Non Communicable Diseases   (Pakistan)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g FAISALABAD MEDICAL UNIVERSITY   (Pakistan)

^h NATIONAL INSTITUTE OF CARDIOVASCULAR DISEASES   (Pakistan)

ⁱ PUNJAB INSTITUTE OF CARDIOLOGY   (Pakistan)

^j Karachi Institute of Heart Diseases   (Pakistan)

^k Red Crescent Institute of Cardiology   (Pakistan)

^l CIVIL HOSPITAL   (Pakistan)

^m UNIVERSITY OF WASHINGTON   (United States)

ⁿ WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^o UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; LIPOPROTEIN A; BIOLOGICAL MARKER; ISOPROTEIN;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; GENE FREQUENCY; GENETIC RISK; GENETIC VARIABILITY; HUMAN; LPA GENE; MAJOR CLINICAL STUDY; MALE; MENDELIAN RANDOMIZATION ANALYSIS; PAKISTANI; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HEART INFARCTION; INCIDENCE; MIDDLE AGED; PAKISTAN; PHENOTYPE; PROCEDURES; RISK FACTOR;

APOPROTEIN(A); BIOMARKERS; CASE-CONTROL STUDIES; CORONARY DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INCIDENCE; LIPOPROTEIN(A); MALE; MENDELIAN RANDOMIZATION ANALYSIS; MIDDLE AGED; MYOCARDIAL INFARCTION; PAKISTAN; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN ISOFORMS; RISK FACTORS;

EID: 85017346584     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30088-8     Document Type: Article

References (30)

1. Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302 (2009), 412–423.
2. Clarke, R, Peden, JF, Hopewell, JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 361 (2009), 2518–2528.
3. Erqou, S, Thompson, A, Di, AE, et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol 55 (2010), 2160–2167.
4. Kamstrup, PR, Tybjaerg-Hansen, A, Steffensen, R, Nordestgaard, BG, Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301 (2009), 2331–2339.
5. Thanassoulis, G, Campbell, CY, Owens, DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 368 (2013), 503–512.
6. Anuurad, E, Boffa, MB, Koschinsky, ML, Berglund, L, Lipoprotein(a): a unique risk factor for cardiovascular disease. Clin Lab Med 26 (2006), 751–772.
7. Kronenberg, F, Utermann, G, Lipoprotein(a): resurrected by genetics. J Intern Med 273 (2013), 6–30.
8. Tsimikas, S, Viney, NJ, Hughes, SG, et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet 386 (2015), 1472–1483.
9. Viney, NJ, van Capelleveen, JC, Geary, RS, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 388 (2016), 2239–2253.
10. Leibundgut, G, Scipione, C, Yin, H, et al. Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J Lipid Res 54 (2013), 2815–2830.
11. Saleheen, D, Zaidi, M, Rasheed, A, et al. The Pakistan Risk of Myocardial Infarction Study: a resource for the study of genetic, lifestyle and other determinants of myocardial infarction in South Asia. Eur J Epidemiol 24 (2009), 329–338.
12. Nikpay, M, Goel, A, Won, HH, et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet 47 (2015), 1121–1130.
13. Wain, LV, Verwoert, GC, O'Reilly, PF, et al. Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet 43 (2011), 1005–1011.
14. Willer, CJ, Schmidt, EM, Sengupta, S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet 45 (2013), 1274–1283.
15. Berndt, SI, Gustafsson, S, Magi, R, et al. Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet 45 (2013), 501–512.
16. Scott, RA, Lagou, V, Welch, RP, et al. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet 44 (2012), 991–1005.
17. Marcovina, SM, Hobbs, HH, Albers, JJ, Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature. Clin Chem 42 (1996), 436–439.
18. Marcovina, SM, Albers, JJ, Scanu, AM, et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem 46 (2000), 1956–1967.
19. Byun, YS, Lee, JH, Arsenault, BJ, et al. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. J Am Coll Cardiol 65 (2015), 1286–1295.
20. Abecasis, GR, Altshuler, D, Auton, A, et al. A map of human genome variation from population-scale sequencing. Nature 467 (2010), 1061–1073.
21. Palmer, TM, Lawlor, DA, Harbord, RM, et al. Using multiple genetic variants as instrumental variables for modifiable risk factors. Stat Methods Med Res 21 (2012), 223–242.
22. Seimon, TA, Nadolski, MJ, Liao, X, et al. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab 12 (2010), 467–482.
23. Fefer, P, Tsimikas, S, Segev, A, et al. The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularization. Cardiovasc Revasc Med 13 (2012), 11–19.
24. Snyder, ML, Hay, RV, Whitington, PF, Scanu, AM, Fless, GM, Binding and degradation of lipoprotein(a) and LDL by primary cultures of human hepatocytes. Comparison with cultured human monocyte-macrophages and fibroblasts. Arterioscler Thromb 14 (1994), 770–779.
25. Haffner, S, Orchard, T, Stein, E, Schmidt, D, LaBelle, P, Effect of simvastatin on Lp(a) concentrations. Clin Cardiol 18 (1995), 261–267.
26. Visser, ME, Wagener, G, Baker, BF, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J 33 (2012), 1142–1149.
27. Raal, FJ, Giugliano, RP, Sabatine, MS, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol 63 (2014), 1278–1288.
28. Nicholls, SJ, Ruotolo, G, Brewer, HB, et al. Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients. J Clin Lipidol 10 (2016), 519–527.
29. Lanktree, MB, Rajakumar, C, Brunt, JH, Koschinsky, ML, Connelly, PW, Hegele, RA, Determination of lipoprotein(a) kringle repeat number from genomic DNA: copy number variation genotyping using qPCR. J Lipid Res 50 (2009), 768–772.
30. Kyriakou, T, Seedorf, U, Goel, A, et al. A common LPA null allele associates with lower lipoprotein(a) levels and coronary artery disease risk. Arterioscler Thromb Vasc Biol 34 (2014), 2095–2099.